These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9140633)

  • 21. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QTc interval in a sample of long-term schizophrenia inpatients.
    Ramos-Ríos R; Arrojo-Romero M; Paz-Silva E; Carballal-Calvo F; Bouzón-Barreiro JL; Seoane-Prado J; Codesido-Barcala R; Crespí-Armenteros A; Fernández-Pérez R; López-Moríñigo JD; Tortajada-Bonaselt I; Diaz FJ; de Leon J
    Schizophr Res; 2010 Jan; 116(1):35-43. PubMed ID: 19892525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
    Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
    Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.
    Remington G; Seeman P; Feingold A; Mann S; Shammi C; Kapur S
    J Clin Psychiatry; 2011 Aug; 72(8):1042-8. PubMed ID: 20868639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular pressure in schizophrenic patients treated with psychiatric medications.
    Souza VB; Moura Filho FJ; Souza FG; Pereira Filho SA; Coelho SS; Furtado FA; Gonçalves TB; Vasconcelos KF
    Arq Bras Oftalmol; 2008; 71(5):660-4. PubMed ID: 19039459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. People living with psychotic illness in 2010: the second Australian national survey of psychosis.
    Morgan VA; Waterreus A; Jablensky A; Mackinnon A; McGrath JJ; Carr V; Bush R; Castle D; Cohen M; Harvey C; Galletly C; Stain HJ; Neil AL; McGorry P; Hocking B; Shah S; Saw S
    Aust N Z J Psychiatry; 2012 Aug; 46(8):735-52. PubMed ID: 22696547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
    Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
    Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
    Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM
    Neuropsychopharmacology; 2003 May; 28(5):995-1003. PubMed ID: 12700715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study.
    Mortimer AM; Al-Agib AO
    Int J Soc Psychiatry; 2007 Mar; 53(2):99-107. PubMed ID: 17472084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
    Behdani F; Hebrani P; Rezaei Ardani A; Rafee E
    Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.